Navigation Links
Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
Date:9/24/2009

ATLANTA, Sept. 24 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), was pleased to hear the announcement today of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine owned by Sanofi-Aventis and Global Solutions for Infectious Diseases. The completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.

Robert McNally, Ph.D., Chief Executive Officer and President stated, "The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the U.S. Army and the U.S. National Institutes of Health (NIH)."

"The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody," said Dr. Harriet Robinson, Senior Vice President of Research & Development. "The two vaccines that have failed in previous efficacy trials elicited only antibody or only T cells. This was the first efficacy test of a vaccine that elicited both antibody and T cells and is very encouraging for the GeoVax vaccine, because our vaccine generates higher frequencies of T cells and better quality antibody. Given what we know about the elicited responses observed in this study, and the similarities and differences between our vaccine and the Sanofi-Aventis vaccine, the GeoVax vaccine should be poised for a higher level of protective success than the 30% success rate achieved in Thailand," noted Dr. Robinson.

"Within the two main areas of focus for our HIV/AIDS v
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
2. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
3. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
4. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
5. Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia
6. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
11. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... LA JOLLA, Calif., Jan. 17, 2012  Synthetic Genomics Inc. ... solutions to solve a wide range of global challenges, ... Vice President for Nutritional Products. Stagnitti is a proven ... translating these into high value food and nutritional products ...
... Jan. 17, 2012 Reliv International, Inc. (NASDAQ: ... of LunaRich™, an exclusive soy powder developed at the Missouri ... of its nutritional supplements and will reveal that product at ... "Biotechnology is vital to Missouri,s economic future," said ...
... Inc. (NASDAQ: VVUS ) today announced that ... The Journal of Sexual Medicine (JSM), a peer-reviewed ... randomized, placebo-controlled, phase 3 study evaluating the safety and ... by the Food and Drug Administration (FDA) for the ...
Cached Biology Technology:Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 2Reliv and Soy Labs Launch LunaRich, a Healthier Soy 3Reliv and Soy Labs Launch LunaRich, a Healthier Soy 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 2REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 3REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 4REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 5REVIVE Trial Results for Avanafil Published in JSM Demonstrate Significant Improvement in Erectile Function 6
(Date:12/17/2014)... -- Automation is fundamentally transforming the travel experience and ... borders. Over the past decade, ePassports, biometric readers, ... to self process through border control via eGates ... increasing number of airports, seaports, and land borders ... Maxine Most , Principal at Acuity Market ...
(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... aimed at preventing cervical cancer is nearly 100 percent effective ... for most cases of cervical cancer. Results of a nationwide ... 9 issue of the New England Journal of Medicine. , ... deaths in women worldwide, resulting in nearly half a million ...
... helping to build a compelling case for oncolytic ... many cancers. , Reovirus, a non-pathogenic ... has shown powerful anti-cancer activity against cultured tumor ... trials. Oncolytics' proprietary reovirus formulation, Reolysin®, is active ...
... Universitat Autònoma de Barcelona, in cooperation with the animal ... model which faithfully reproduces the characteristics of dog’s skin ... various lines of research related to skin biology and ... The basic structure of skin consists of an external ...
Cached Biology News:Study shows continued success for new HPV vaccine against virus responsible for cervical cancer 2Dealing deadly cancers a knockout punch 2Dealing deadly cancers a knockout punch 3
Human M-CSF...
Human Serpin B5/Maspin Affinity Purified Polyclonal Ab...
... and S.J. Allen (1995) This ... world authorities on current issues relating to ... Several major advances have been made recently ... disease. Topics include molecular neuropathology through clinical ...
Normal human serum, single donor...
Biology Products: